Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHT34O)

Drug Name
Gemifloxacin Drug Info
Synonyms
Factiv; Factive; Gemifloxacin [INN]; Gemifloxacin mesilate; LB 20304; LB 20304a; SB 265805; Factiv (TN); Factive (TN); Gemifloxacin (INN); LB-20304; SB-265805; 7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Mycoplasma pneumoniae pneumonia Approved [2]
Streptococcal pneumonia Approved [2]
Pneumonia caused by chlamydia Investigative [2]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [2]
Therapeutic Class
Antibiotics
Cross-matching ID
PubChem CID
9571107
ChEBI ID
CHEBI:101853
CAS Number
CAS 175463-14-6
TTD Drug ID
DMHT34O
VARIDT Drug ID
DR00688
ACDINA Drug ID
D00301

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Bacterial DNA gyrase (Bact gyrase)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Grepafloxacin DMGLX0T Chronic bronchitis CA20.1 Approved [5]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [3]
Levofloxacin DMS60RB Acute maxillary sinusitis Approved [3]
Gatifloxacin DMSL679 Acute gonococcal cervicitis Approved [3]
Norfloxacin DMIZ6W2 Acute gonococcal cervicitis Approved [3]
Ozenoxacin DM6KZMG Impetigo 1B72 Approved [6]
Sparfloxacin DMB4HCT Bacterial infection 1A00-1C4Z Approved [3]
Besifloxacin DMPHXMI Ocular inflammation 9C61.24 Approved [7]
Finafloxacin DMZEONG Urinary tract infection GC08 Approved [8]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Staphylococcus Topoisomerase IV (Stap-coc parC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [3]
Levofloxacin DMS60RB Acute maxillary sinusitis Approved [3]
Gatifloxacin DMSL679 Acute gonococcal cervicitis Approved [3]
Ozenoxacin DM6KZMG Impetigo 1B72 Approved [6]
Sparfloxacin DMB4HCT Bacterial infection 1A00-1C4Z Approved [3]
Besifloxacin DMPHXMI Ocular inflammation 9C61.24 Approved [7]
Finafloxacin DMZEONG Urinary tract infection GC08 Approved [8]
Delafloxacin Meglumine DMVTU5Q Acute bacterial skin infection 1C41 Approved [9]
Moxifloxacin DMU8V4S Bacterial infection 1A00-1C4Z Approved [3]
Zabofloxacin DMEY1F3 Pneumonia CA40 Phase 3 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Multidrug resistance-associated protein 2 (ABCC2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [11]
Methotrexate DM2TEOL Anterior urethra cancer Approved [12]
Folic Acid DMEMBJC Colorectal carcinoma Approved [13]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [14]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [15]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [16]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [17]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [18]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [19]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [3]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [4]

References

1 Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
2 Gemifloxacin FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33.
5 Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
6 In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
7 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
8 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
9 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
10 DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
11 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
12 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
13 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
14 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
15 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
16 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
17 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
18 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
19 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
20 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.